‹ Screener

MEDICINOVA INC

MNOV · Pharmaceutical Preparations · 49.2M shares · +0%/yr ↑ dilution · EDGAR filings ↗
Net buyback after stock comp: -$1M (gross -$8K, SBC $1M)

Grade

D44

Clinical/early-stage biotech — deep losses but funded.

Strengths

Risks

Notable findings

Quarterly revenue

2023-12-31 · $02025-09-30 · $123K2025-12-31 · $152K2026-03-31 · $187K

Last 4 quarters · from SEC filings.

Key metrics

Operating margin
-3242.5%
Net margin
-2928.8%
Return on equity
-28.9%
Return on assets
-26.3%
Revenue growth (QoQ)
23.2%
Current ratio
8.2×
Free cash flow
-$10M
EBITDA
-$13M
Tangible book value
$32M
Cash & investments
$31M
Cash runway
13q
Stock comp / revenue
202.4%

Notable events (8-K)

DateItems
2026-06-24Shareholder votefiling ↗
2026-02-20ResultsExhibitsfiling ↗
2025-12-30Material agreementExhibitsfiling ↗
2025-08-01Material agreementExhibitsfiling ↗
2025-06-18Shareholder votefiling ↗
2025-03-11Reg FDExhibitsfiling ↗
2024-06-12Shareholder votefiling ↗
2024-04-01Exec/director changefiling ↗

Recent filings

FormFiledPeriodAccession
8-K2026-06-242026-06-230001193125-26-281171 ↗
10-Q2026-05-142026-03-310001193125-26-224066 ↗
10-K2026-03-102025-12-310001193125-26-100432 ↗
8-K2026-02-202026-02-200001193125-26-060232 ↗
8-K2025-12-302025-12-290001193125-25-335917 ↗
10-Q2025-11-122025-09-300001193125-25-277779 ↗
10-Q2025-08-142025-06-300000950170-25-109041 ↗
8-K2025-08-012025-07-300001193125-25-170744 ↗
8-K2025-06-182025-06-170000950170-25-087924 ↗
10-Q2025-05-132025-03-310000950170-25-070461 ↗
8-K2025-03-112025-03-110001193125-25-051990 ↗
10-K2025-02-192024-12-310000950170-25-023301 ↗